Aytu BioPharma Q3 revenue $22.7M (-6% YoY); net loss narrows to $7.2M

AYTU BIOPHARMA, INC

2023-Q3 EPS reported -$4.71 revenue$76,667,000

Total net revenue $22.7M, down 6% from $24.2M; net loss ($7.2M) vs ($53.3M) last year.
Record total prescriptions 153,452 (+32% YoY); ADHD prescriptions up 27%.
Rx segment revenue $13.8M; ADHD revenue down 21% to $8.3M due to $1.2M channel inventory adjustment.
Pediatric products revenue up 81% to $5.3M; Consumer Health down 14% to $8.9M.
Gross margin improved to 56% from 52%; cash $19.2M; FDA approval for Adzenys manufacturing transfer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AYTU BIOPHARMA, INC reported the quarter ended March 31, 2023 results: revenue $22.7 million, net income $(7.2) million, EPS ($1.93) per share.

Period: the quarter ended March 31, 2023
Revenue: $22.7 million
Net income: $(7.2) million
EPS: ($1.93) per share
Result: reported results

Exact text from the filing

Q3 2023 Commercial Highlights (3 months ending March 31, 2023) ● Total net revenue was $22.7 million, a decrease of 6% from the $24.2 million in net revenue in the year-ago quarter. Revenue during Q3 2023 was impacted by a one-time $1.2 million channel inventory adjustment due to an ADHD products price increase instituted on April 1, 2023. Excluding this impact, net revenue would have been $23.9 million, in-line with the year-ago quarter. ● Record total quarterly prescriptions of 153,452, a 32% increase over Q3 2022. ● Net revenue from the Company’s Rx segment was $13.8 million during Q3 2023 compared to $13.9 million in the year-ago quarter. o ADHD products (Adzenys XR-ODT® and Cotempla XR-ODT®) net revenue decreased by 21% to $8.3 million from $10.4 million in the year ago quarter. o Pediatric products (Poly-Vi-Flor®, Tri-Vi-Flor®, and Karbinal® ER) net revenue increased 81% to $5.3 million, from $2.9 million in the year-ago quarter. ● Consumer Health revenue during Q3 2023 was $8.9

View on SEC.gov

Browse all earnings releases →

AYTU BIOPHARMA, INC filing history →

Source: SEC EDGAR

accession 0001558370-23-009383

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.